
Researchers at the University of Pennsylvania’s Perelman School of Medicine have discovered that people with psoriasis are more at risk …

Sanofi readjusted its 2017 financial expectations after its third-quarter results came in lower than projected. The company revealed that net …

Sanofi has launched a lawsuit against Mylan as part of a dispute that alleges that the latter infringed upon 18 …

In the first ever study of its kind, researchers from the University of Surrey examined the records of more than …
Novo Nordisk is celebrating the news that its diabetes drug semaglutide has won the favour of FDA experts, with one …

Sanofi Aventis Nigeria plans to put together a National Diabetes Summit to address crisis in the country as five million …

Johnson & Johnson’s Animas Corporation will cease business and close operations after the pharma giant could not find a buyer …

Sanofi has promoted Stefan Oelrich to the position of Executive Vice President of Diabetes and Cardiovascular (DCV), giving him a …

Novo Nordisk has unveiled new data on its diabetes treatment Xultophy (insulin degludec/liraglutide) which supports its efficacy in reducing risk …

Novo Nordisk has resolved a probe by the US Justice Department which accused the Danish drugmaker of illegal marketing activities …

Novo Nordisk has revealed that its diabetes drug semaglutide managed to outperform Eli Lilly’s own treatment dulaglutide (Trulicity) in controlling …

A study emerging from St George’s University of London found that children who slept an hour less than the recommended …

A report from the Royal College of Paediatrics and Child Health (RCPCH) has highlighted a “hugely disturbing” rise in cases …

Another week, another busy week in pharma. The last seven days have seen some remarkable strides in the diabetes space, …

In a first for the disease area, an immunotherapy treatment for diabetes, developed by researchers at King’s College London and …